(Q91137768)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

title

Targeting mitochondria in cancer: current concepts and immunotherapy approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

1 reference

Sergey Pustylnikov

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Francesca Costabile

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Silvia Beghi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Andrea Facciabene

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

publication date

31 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

volume

202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

page(s)

35-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

cites work

Mitochondria and Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

7 January 2021

Mitochondria and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Acid-base titration across the membrane system of rat-liver mitochondria. Catalysis by uncouplers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Oxidants, oxidative stress and the biology of ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

On the Origin of Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Understanding the Warburg effect: the metabolic requirements of cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial DNA variant 16189T>C is associated with susceptibility to endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial C150T polymorphism increases the risk of cervical cancer and HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial energetics and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial metabolism and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

7 January 2021

SDH mutations in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Structural basis of fumarate hydratase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Wnt signaling regulates mitochondrial physiology and insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial mutations in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondria are the powerhouses of immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Tolerance and exhaustion: defining mechanisms of T cell dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Molecular and cellular insights into T cell exhaustion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

T-cell exhaustion in the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

T cell metabolic fitness in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Ras, PI(3)K and mTOR signalling controls tumour cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Tumor suppressors and cell metabolism: a recipe for cancer growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Overcoming T cell exhaustion in infection and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell Activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

T cells: Mitochondrial shape shifters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

During autophagy mitochondria elongate, are spared from degradation and sustain cell viability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Metabolic pathways in immune cell activation and quiescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Succinate is an inflammatory signal that induces IL-1β through HIF-1α.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Inhibition of macrophage fatty acid β-oxidation exacerbates palmitate-induced inflammatory and endoplasmic reticulum stress responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A small jab - a big effect: nonspecific immunomodulation by vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial DNA damage and its consequences for mitochondrial gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Oxidative stress and antioxidant defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The maintenance of mitochondrial DNA integrity--critical analysis and update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial DNA maintenance: an appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

DNA strand break repair and human genetic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Selective mitochondrial DNA degradation following double-strand breaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A threshold of transmembrane potential is required for mitochondrial dynamic balance mediated by DRP1 and OMA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial threshold effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Origins of mtDNA mutations in ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mechanisms linking mtDNA damage and aging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial genome maintenance in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial biogenesis and clearance: a balancing act.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Cross-talk between AMPK and mTOR in regulating energy balance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial fission facilitates the selective mitophagy of protein aggregates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial dynamics and mitochondrial quality control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A vesicular transport pathway shuttles cargo from mitochondria to lysosomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial fusion and fission in cell life and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

7 January 2021

Mechanisms of mitophagy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

ER-mitochondria contacts: Actin dynamics at the ER control mitochondrial fission via calcium release.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Multiple dynamin family members collaborate to drive mitochondrial division

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Drp1-Dependent Mitochondrial Fission Plays Critical Roles in Physiological and Pathological Progresses in Mammals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mechanisms, pathophysiological roles and methods for analyzing mitophagy - recent insights.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

PINK1 autophosphorylation is required for ubiquitin recognition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phosphorylated ubiquitin chain is the genuine Parkin receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Genetic determinants at the interface of cancer and neurodegenerative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Parkin as a tumor suppressor gene for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

An emerging role of PARK2 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The concept of immune surveillance against tumors. The first theories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondria in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial DNA in innate immune responses and inflammatory pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Circulating mitochondrial DAMPs cause inflammatory responses to injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondria: master regulators of danger signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Roles of Mitochondrial DNA Signaling in Immune Responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Role of MHC class I in immune surveillance of mitochondrial DNA integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Experimental evidence that mutated-self peptides derived from mitochondrial DNA somatic mutations have the potential to trigger autoimmunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The Human Immune System Recognizes Neopeptides Derived from Mitochondrial DNA Deletions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Autophagy proteins in antigen processing for presentation on MHC molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial defects in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Cancer therapy: Targeting mitochondria and other sub-cellular organelles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Targeting mitochondria metabolism for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Targeting mitochondria for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Tumor glycolysis as a target for cancer therapy: progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Targeting cellular metabolism to improve cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Metformin and reduced risk of cancer in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The insulin and insulin-like growth factor receptor family in neoplasia: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

AMPK: a target for drugs and natural products with effects on both diabetes and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial metabolism and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Elesclomol induces cancer cell apoptosis through oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial membrane permeabilization in cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A novel, high conductance channel of mitochondria linked to apoptosis in mammalian cells and Bax expression in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Anti-apoptotic genes Bcl-2 and Bcl-xL overexpression can block iridovirus serine/threonine kinase-induced Bax/mitochondria-mediated cell death in GF-1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Selective targeting of bioactive compounds to mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Bacterial signal peptide recognizes HeLa cell mitochondrial import receptors and functions as a mitochondrial leader sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

DNA-protein conjugates can enter mitochondria via the protein import pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Targeting mitochondria with organelle-specific compounds: strategies and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondria-penetrating peptides: sequence effects and model cargo transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondria-penetrating peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Delivery of drugs and macromolecules to the mitochondria for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Facile detection of mitochondrial DNA mutations in tumors and bodily fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitochondrial DNA mutations in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

CD4+ T-cell response to mitochondrial cytochrome B in human melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

Mitophagy in Parkinson's Disease: Pathogenic and Therapeutic Implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

DNA vaccine for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2018.07.013

10.1016/J.TRSL.2018.07.013

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30144423%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

PubMed publication ID

30144423

1 reference